Finorex10 mg

Finorex is a nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) with an established, guideline-supported indication:

• Chronic kidney disease (CKD) associated with type 2 diabetes mellitus: Finorex is indicated to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with CKD associated with type 2 diabetes.

Finorex is typically used as an add-on to standard-of-care therapy, including a maximally tolerated dose of an ACE inhibitor or ARB, and in patients with type 2 diabetes who are receiving appropriate glycemic control measures. It is not a substitute for these background therapies.

Each film-coated tablet contains Finerenone as the active ingredient, available in strengths of 10 mg and 20 mg, along with pharmaceutically inert excipients that aid tablet formulation, stability, and dissolution.

Finorex is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR). Overactivation of the MR by aldosterone and other corticosteroids is believed to contribute to fibrosis and inflammation that drive progression of kidney and cardiovascular disease in patients with chronic kidney disease and type 2 diabetes. Unlike older steroidal MRAs (such as spironolactone or eplerenone), Finorex has a distinct chemical structure that gives it high selectivity for the mineralocorticoid receptor over androgen, progesterone, glucocorticoid, and estrogen receptors, with balanced distribution between the kidney and heart.

Finorex is supplied as an oral tablet and is taken once daily.

Finorex belongs to the class of nonsteroidal mineralocorticoid receptor antagonists (MRAs). It is pharmacologically and structurally distinct from steroidal MRAs such as spironolactone and eplerenone.

Finerenone works by blocking the mineralocorticoid receptor (MR), a nuclear receptor that, when overactivated by aldosterone, mediates sodium reabsorption and drives pathological processes such as fibrosis, inflammation, and hypertrophy in the kidney and cardiovascular tissue.

Mechanism of Action

By antagonizing MR overactivation, Finerenone reduces MR-mediated sodium reabsorption and blocks the downstream inflammatory and fibrotic pathways implicated in the progression of diabetic kidney disease and associated cardiovascular events.

Pharmacokinetics

• Absorption: Finerenone is rapidly absorbed after oral administration, with peak plasma concentrations reached within approximately 1 hour; absolute bioavailability is about 44%. It may be taken with or without food.
• Distribution: Highly protein-bound (~90%), predominantly to serum albumin.
• Metabolism: Extensively metabolized, primarily via the CYP3A4 enzyme system and to a lesser extent CYP2C8.
• Elimination: Eliminated with an effective half-life of approximately 2–3 hours; excreted mainly via the kidneys and feces as metabolites, with negligible amounts as unchanged drug.

Finorex tablets are taken orally, once daily, with or without food. Tablets should be swallowed whole; if a patient cannot swallow the tablet whole, it may be crushed and mixed with water or applesauce immediately before use. Do not initiate a missed dose late in the day to "catch up" — simply resume the normal schedule the next day.

Strong CYP3A4 Inhibitors

Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir, nelfinavir, cobicistat, clarithromycin) markedly increases Finorex exposure and hyperkalemia risk. This combination is contraindicated. Grapefruit and grapefruit juice should also be avoided, as they can act as moderate-to-strong CYP3A4 inhibitors.

Moderate and Weak CYP3A4 Inhibitors

Concomitant use with moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole, diltiazem, verapamil) increases Finorex exposure; more frequent serum potassium monitoring is recommended during initiation or dose adjustment.

CYP3A4 Inducers

Strong or moderate CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) can substantially reduce Finorex plasma concentrations and efficacy; concomitant use with strong or moderate inducers should be avoided.

Other Potassium-Elevating Agents

Concomitant use with ACE inhibitors, angiotensin receptor blockers (ARBs), potassium-sparing diuretics, potassium supplements, or trimethoprim increases the risk of additive hyperkalemia and requires more frequent potassium monitoring (see Precautions and Warnings).

The most common and clinically important adverse effect of Finorex is hyperkalemia. Other adverse effects reported in clinical trials include:

• Hyperkalemia (elevated blood potassium) — the most frequent adverse reaction; see Precautions and Warnings for monitoring guidance.
• Hypotension (low blood pressure), particularly in patients also on antihypertensive therapy.
• Hyponatremia (low blood sodium).

Less common effects may include mild gastrointestinal upset. Patients should promptly report symptoms such as muscle weakness, irregular heartbeat, dizziness, or fainting, which may indicate hyperkalemia or hypotension.

Pregnancy: Data on the use of Finorex in pregnant women are limited. Animal studies have shown developmental toxicity at exposures several times the human exposure at the maximum recommended dose. Finorex should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: There is no data on the presence of Finorex in human milk or its effects on the breastfed infant or on milk production. Because of the potential for adverse effects in a breastfed infant, breastfeeding is not recommended during treatment with Finorex and for approximately one day after the last dose. Consult a physician regarding infant feeding during treatment.

Hyperkalemia

Finorex can cause hyperkalemia, which is its most important safety concern. Risk increases with lower eGFR, higher baseline potassium, and concomitant use of other potassium-elevating drugs (see Interactions).

• Do not initiate Finorex if serum potassium is greater than 5.0 mEq/L.
• Measure serum potassium and eGFR before starting treatment, at 4 weeks after initiation or dose adjustment, and periodically thereafter based on individual patient characteristics.
• If serum potassium rises above 5.5 mEq/L, interrupt Finorex and restart at 10 mg once daily (or the previous lower dose) when potassium falls to 5.0 mEq/L or below.
• Advise patients to avoid potassium-rich salt substitutes without medical advice and to seek prompt medical attention for symptoms of hyperkalemia such as muscle weakness, palpitations, or irregular heartbeat.

Hepatic Impairment

Use in patients with severe hepatic impairment is not recommended, as Finorex exposure may be increased. Use with caution and monitor potassium more closely in moderate hepatic impairment.

General Monitoring

Kidney function (eGFR) should be monitored periodically during treatment, particularly around dose initiation and titration.

The most likely manifestation of Finorex overdose is hyperkalemia and/or hypotension. There is no specific antidote. If overdose is suspected, Finorex treatment should be interrupted immediately and the patient should seek immediate medical attention or contact emergency services/a poison control center. Management should focus on standard supportive care, including close monitoring of serum potassium, blood pressure, and cardiac status; given the high protein binding of Finorex (~90%), hemodialysis is unlikely to be effective in significantly removing the drug. Do not attempt to manage a suspected overdose at home without medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Finorex is indicated specifically for use in patients with chronic kidney disease; dosing is guided by eGFR (see Dosage and Administration). Use is not recommended in patients on chronic dialysis, as safety and efficacy have not been established in this population.

Hepatic Impairment

No dose adjustment is needed in mild or moderate hepatic impairment, though closer potassium monitoring is advised in moderate impairment. Use in severe hepatic impairment is not recommended (see Precautions and Warnings).

Elderly

No overall differences in effectiveness were observed between elderly and younger patients; elderly patients, particularly those with reduced renal function, may be at increased risk of hyperkalemia and should be monitored closely.

Pediatric Use

Safety and efficacy have not been established in patients under 18 years of age; see Pediatric Uses.

Finorex is intended for long-term, typically indefinite, once-daily use in eligible patients with chronic kidney disease associated with type 2 diabetes, as part of ongoing management to slow kidney disease progression and reduce cardiovascular risk. Treatment duration should be determined by the prescribing physician based on ongoing assessment of kidney function, potassium levels, and overall clinical benefit. Do not stop Finorex without consulting a physician.

Nonsteroidal mineralocorticoid receptor antagonist (MRA).

Finerenone selectively blocks the mineralocorticoid receptor, preventing aldosterone-driven overactivation that promotes sodium retention, inflammation, and fibrosis in the kidney and cardiovascular system. This action underlies its ability to slow progression of diabetic kidney disease and reduce associated cardiovascular events.

The safety and efficacy of Finorex have not been established in pediatric patients (under 18 years of age). Finorex is not recommended for use in children or adolescents outside of clinical trial settings, and its use in this population should only occur under close specialist supervision if considered necessary.